Results 81 to 90 of about 73,193 (159)

Treatment of Livedoid Vasculopathy with the Janus Kinase Inhibitors: A Case Series. [PDF]

Case Rep Dermatol
Zhao G, Liu Y, Ni J, Song Z.
europepmc   +1 more source

Janus Kinase Family [PDF]

, 2020
openaire   +1 more source

Janus Kinase Inhibitor Discontinuation at a UK Tertiary Centre: A Retrospective Study. [PDF]

Cureus
Bland K, Jubber A, Ganguly S, Moorthy A.
europepmc   +1 more source

Retraction: The Association Between Janus Kinase 2 and Factor V Leiden Mutations and Thrombotic Complications in Patients With Myeloproliferative Disorders: A Study From Saudi Arabia. [PDF]

Cureus
Sayed WS, Al-Bayati A, Elzubair LG, Mohamed S, Alharthi M.   +4 more
europepmc   +1 more source

Acute retinal necrosis during the systemic use of Janus kinase inhibitor. [PDF]

Int J Retina Vitreous
Watanabe D, Namba K, Hase K, Suzuki K, Ogino Y, Saito M, Iwata D, Mizuuchi K, Hiraoka M, Narita M, Kitaichi N, Kitaya N, Ishida S.   +12 more
europepmc   +1 more source

Management of Pregnancy in Women with Inflammatory Bowel Disease: Positioning Janus Kinase Inhibitors Within Current Evidence. [PDF]

Curr Issues Mol Biol
Colacurci D, Pellegrino R, Lamart A, Staiano D, De Costanzo I, Izzo M, Imperio G, Landa F, Scamardella G, Di Lella E, Federico A, Sarno L, Gravina AG.   +12 more
europepmc   +1 more source

Short-term omalizumab as a potential rescue therapy for alopecia areata flares during Janus kinase inhibitor maintenance. [PDF]

JAAD Int
Wang Q, Cheng K, Lin JM, Tao K, Xu M, Zhang X, Tang S, Ni C, Wu W, Lin J.   +9 more
europepmc   +1 more source

Janus kinase (JAK) [PDF]

Science-Business eXchange, 2014
openaire   +1 more source

Content validation of the Myelofibrosis Symptom Assessment Form version 4.0 (MFSAF v4.0) in Janus kinase inhibitor-experienced patients with myelofibrosis. [PDF]

J Patient Rep Outcomes
Cutts K, Cardellino A, Zhang S, Phiri K, Gelhorn H.   +4 more
europepmc   +1 more source